MHT: weighing benefit against risk, properly this time.
Reviewed Dr Jo Mackson, MBBS FRACGP
Published July 2026
Reading time 30 mins, 5 to 7 mins per part
Short on time? Start with the Mini Guide, then come back here when you want the full picture.
This is not a guide that will tell you MHT is a miracle, in much the same way it would never tell you it’s a menace. It is a careful look at what MHT can do, what it cannot, and what that means for you, so you can make up your own mind.
In 2002, a single study changed how a generation of women were cared for. The Women’s Health Initiative reported that hormone therapy raised the risk of breast cancer, the headlines travelled around the world, and within a year prescriptions fell off a cliff. Women already on MHT stopped. Women who came after were never offered it at all, and on the rare occasions it was raised, it came so shrouded in fear and warnings that they often declined. The fear was real. But so was the harm of going without. A generation of women lived through hot flushes, broken sleep, thinning bones, and vaginal and urinary symptoms that a safe treatment could have eased, because a study had frightened everyone, including their doctors, away from it.
We have now had more than twenty years to read the study properly, to run better ones, and to separate what MHT actually does from what we were afraid it did.
The women harmed by 2002 were not the ones who took MHT. They were the ones frightened away from it, left without protection for their bones, their hearts, and their minds, and for years with symptoms a safe treatment could have eased.
This guide is here to set the record straight, or at least as straight as we can with the evidence we have. We will set out the benefits without overselling them, including the promising ones the science is still working out. And we will be clear about the risks without inflating them, because women have been misled in both directions. Our job here is to educate, not to talk you into anything or out of it. The decision is yours; the information should be too.
You deserve to see the whole picture: what we know, what we do not yet, and how it might apply to you and your own risks. The best decisions about your health are shared ones, made with your doctor, and a decision cannot be shared if only one of you knows the evidence.
The nuance behind the risk.
There is no single MHT, and no single risk number.
If you have ever tried to find a straight answer to “is MHT safe”, you have probably noticed that every answer arrives wrapped in a “well, it depends”. That is not doctors being evasive. It is the honest shape of the truth. There is no single type of MHT, and there is no “average risk” of any particular condition or disease that applies to every woman.
The oestrogen in MHT can be swallowed as a tablet, or absorbed through the skin as a patch or gel. If you have a uterus, that oestrogen is paired with a progestogen to protect the lining, and that progestogen can be micronised progesterone, which is body-identical, or an older synthetic version, with the choice depending on several factors. The dose can be higher or lower. It can be started at 42 or at 62. Each of those choices changes the benefits, the risks, or both. So when a study, a headline, or a friend tells you “MHT does X”, the first useful question is always the same: which MHT, given how, to whom, and when.
The four things that change the picture.
Four things influence the balance of benefit and risk, and each of these elements needs to be considered to make an informed decision about the risks and benefits of taking MHT.
Your baseline and your age. Risk is not a switch that is simply on or off, safe or dangerous. It is always measured against the risk you already carry, and the single biggest thing shaping that is your age. Other things lift or lower it too: your family history, your personal medical history, your weight, how much you drink, and whether you smoke. So the same MHT, given to one woman, can carry a risk that is small enough to set aside, while for another, with a higher starting point, the same decision deserves more thought.
The type. Oestrogen on its own behaves differently from oestrogen combined with a progestogen. And within combined therapy, micronised progesterone behaves differently from the older synthetic progestogens, particularly when it comes to breast cancer.
The route. Whether the oestrogen is swallowed or absorbed through the skin changes the risk of blood clots in the legs, lungs or brain. When the oestrogen part of MHT is taken orally as a tablet, it passes through the liver first, where it can increase the production of several clotting factors, making the blood a little more prone to clotting. When oestrogen is instead absorbed through the skin as a patch or gel, it skips that step and does not raise the clot risk in the same way.
The timing. Starting MHT around the time of menopause, rather than many years later, is where the balance tips most clearly in your favour. This is the window of opportunity, and we come back to it properly in Part Four.
Almost every frightening number you have read about MHT came from a particular type, given a particular way, to a particular group of women. Change the type, the route, or the age, and you are looking at a different number altogether.
The benefits, settled and emerging.
Symptom relief, the reason most women start.
Most women take MHT for one reason. They feel terrible, and MHT makes them feel better. That is the headline benefit, and it is the one the evidence is clearest on, so it goes first.
Menopause is far more than hot flushes. As oestrogen and progesterone fall, women can experience night sweats, disrupted sleep, low mood and anxiety, brain fog and memory lapses, joint and muscle aches, palpitations, and changes in libido, alongside the vasomotor and genitourinary symptoms most people associate with menopause. MHT, by replacing the hormones that have fallen, can ease many of these.
The evidence is strongest, and the effect largest, for the vasomotor symptoms, the hot flushes and night sweats. Nothing else comes close for moderate to severe symptoms. The mechanism is straightforward once you see it: as oestrogen falls and swings, the part of the brain that regulates body temperature becomes oversensitive, and restoring oestrogen settles that thermostat. The broken sleep that flushes and sweats cause tends to ease with them. For other symptoms, such as low mood or brain fog, MHT helps some women considerably and others less, so it is worth a trial rather than a guarantee.
For genitourinary symptoms, the vaginal dryness, discomfort, and urinary changes that come with falling oestrogen, MHT helps too, and vaginal oestrogen in particular works very well with very little absorbed into the rest of the body.
Vaginal oestrogen is a category of its own.
Low-dose vaginal oestrogen, used for genitourinary symptoms, barely enters the bloodstream. It does not carry the systemic considerations the rest of this guide discusses, it can be used long term, and for many women it is suitable even when tablet or whole-body MHT is not. If your main trouble is vaginal or urinary, this is often the whole answer, and worth raising with your doctor on its own.
Bone and fracture, the other established benefit.
After menopause, the drop in oestrogen speeds up bone loss, and broken bones become more common. MHT slows that loss and lowers the risk of fracture, and this is well established. This benefit is not only for women already diagnosed with osteoporosis; it is seen across all women in this age group, which is part of what makes it valuable. The protection holds while you are taking it and fades gradually after you stop. The Australasian Menopause Society and NICE both list MHT as a first-line option for protecting bone in younger postmenopausal women, particularly those who also have symptoms.
The emerging picture.
Beyond symptoms and bones, there is a growing body of evidence that MHT may do more, for the heart, for the metabolism, and possibly for the brain. For some of this, the heart and metabolism in particular, the evidence is strong and comes from good studies. For the rest, it is promising but not yet clear.
This is also where the conversation gets noisy. Menopause has been under-researched for decades, and the fallout from 2002 set it back further. Into that gap stepped a wellness industry and a wave of online voices, some careful and many not, and at the louder end you will even find MHT sold as a longevity miracle. When some claim far too much, and the science has been too thin for too long, it is understandable that women are frustrated, and can begin to feel that medicine is either holding out on them or not being straight with them, and it’s easy to fall back on the old idea that if something is natural it must be safe, especially when there are convincing meno-influencers online saying exactly that.
Women deserve the full truth, though, not a fresh set of overstatements swapped in for the old fear. Letting the hype outrun the evidence would just be the WHI story in reverse, and women have been failed by that once already. But here is what the evidence actually shows about the benefits of MHT beyond symptoms and bones, with the strength of the evidence marked each time. We are watching this closely, and waiting on better studies so we can advise you with the confidence and clarity women deserve.
Started around the time of menopause, MHT is linked with fewer coronary events, meaning fewer heart attacks and the related problems caused by narrowed arteries around the heart. Started many years later, in arteries that may already carry early atherosclerosis, the fatty build-up that stiffens and narrows blood vessels with age, that benefit disappears, and for some women and some types of MHT there can be a small early increase in risk in the first year or so before it settles. This is the timing story again: for a woman in her fifties, within 10 years of menopause, the signs point to fewer heart events; for a woman starting in her late sixties, MHT does not give the same protection and so should not be started for that purpose.
MHT is linked with fewer new cases of type 2 diabetes, and with better blood-sugar control in women who already have it. The likely reason is that oestrogen improves how the body responds to insulin and helps steer fat away from around the organs. This is encouraging, but again it is not a reason to start MHT on its own. The reason is in how the benefit was found: researchers noticed it while studying MHT for other things, like bones, hearts, and breast cancer, rather than setting out to test metabolism and insulin resistance directly. No trial has yet given MHT to a group of women specifically to see whether it prevents diabetes and followed them over time against a comparison group. Until that study is run, the benefit is worth noting but not solid enough to prescribe for, which is why no menopause guideline recommends MHT to prevent diabetes.
This is the least settled of all. Some studies suggest women who start MHT early have lower rates of dementia later in life, but these are studies that can show a link without proving the hormones caused it, and the trials needed to settle the question have not been done. So we hold possible brain protection as a bonus that may come with starting MHT at the usual time, not a reason to start it, and not something to count on. Timing, though, matters here as much as anywhere: when combined MHT was started in women in their late sixties and seventies, one large trial linked it with a higher rate of dementia, not a lower one. So this is not a treatment to start late in life in the hope of protecting your memory. Early, it may help; late, it may do the harm you were hoping to avoid.
Mortality means the risk of dying from any cause. This is the broadest measure there is, and the one most twisted online, where MHT gets sold as something that will help you live longer. Here is what can fairly be said. The large studies that have followed MHT users for years, including national health records from Finland and Denmark, do not find more deaths among women who take it, and several find slightly fewer among those who start around the time of menopause. These are observational, so they cannot rule out that women who take MHT were simply healthier to start with, which is why we read them as reassuring rather than as proof. The one randomised controlled trial that speaks to this, the Danish Osteoporosis Prevention Study, gave MHT to recently menopausal women and followed them for more than ten years; that group had fewer heart events and fewer deaths, with no rise in clots or stroke.
Put simply, the evidence we have does not show that MHT shortens women’s lives when it is used in the right women at the right time. Some studies even hint that women on MHT live slightly longer, but that finding is worth treating with caution, because it comes mostly from observing groups of women over time rather than from trials built to answer the question directly. The fair summary is that MHT, used appropriately, does not appear to raise your overall risk of dying. That is a reassuring foundation for a decision about something that improves your quality of life, knowing it is not coming at the cost of a shorter one.
The window of opportunity.
You will have noticed the same word running under heart, brain and mortality alike: timing. Starting MHT around the time of menopause, generally before the age of 60 or within 10 years of your last period, is where the benefits are clearest and the risks are smallest. If MHT is started much later, in your late sixties or beyond, the balance shifts the other way: the benefits fade, and some risks rise. This is what is meant by the window of opportunity. It is not a door that slams shut on a particular birthday, it is a gradual change in the risk versus benefit equation, and it is one of the most important things to understand when you are weighing up whether, and when, to start.
The risks, told straight.
Breast cancer, the fear that needs the most care.
Breast cancer is the fear that left two generations of women without hormones after 2002, so it is the one that deserves the most careful handling. Here is what it comes down to: combined MHT carries a small increase in breast cancer risk, that increase depends on which progestogen is used, and oestrogen on its own does not raise the risk at all.
For a woman in her fifties, the background number is about 23 cases of breast cancer per 1,000 women over 5 years. Add oral oestrogen with an older synthetic progestogen and that rises by roughly 4 in 1,000. Use oestrogen with micronised progesterone instead (the body-identical form), and there is no measurable extra risk over the first 5 years, and beyond that there is not yet enough long-term data to say. And for women without a uterus, who can take oestrogen on its own, the data show no increase, and if anything even a small reduction in breast cancer risk.
There is one more thing that is vital to understanding the link between MHT and breast cancer. MHT does not appear to create a breast cancer that was never going to occur. If a woman was never going to develop breast cancer, MHT is not expected to cause it. What it may do is cause it to grow faster, bigger, and present earlier: if very early, slow-growing cancer cells are already present, the hormonal environment created by MHT can let them grow a little faster, so a cancer that was already on its way is found sooner than it otherwise would have been. That is a different, and less frightening, idea than MHT causing breast cancer, and it explains why the increase in breast cancers is seen in current MHT users, but then falls away after stopping.
What deserves as much attention as the fear itself is what the fear has cost. For two decades after 2002, women were left to white-knuckle their way through symptoms that a safe treatment could have eased, told their hot flushes, sleepless nights and low mood were simply the price of getting older. Bones thinned, hearts went unprotected, marriages and careers buckled under symptoms no one was treating, all to avoid a risk that was real but far smaller than the headlines made it sound, and tied to a formulation most women would not be given today. The harm of the fear affected more women than the harm it was protecting them from, and still to this day is an ongoing hurdle for women getting the treatment they need and deserve.
This small added breast risk that does exist also sits in the same territory as everyday factors most women already live with, such as drinking alcohol and increased body weight. So we come back to the same point: the conversation has to move away from a single frightening figure, and towards your own background risk, the things you can change, and what any added risk actually means in real numbers.
Clots and stroke, and why the route matters most.
Another small but notable risk of MHT is blood clots, and stroke, and this risk too is nuanced. It depends far less on whether you take MHT than on how the oestrogen reaches your bloodstream.
When oestrogen is taken orally via a tablet it is absorbed through the gut and passes through the liver in the first part of its metabolism, before it reaches the rest of the body. There it increases the production of several clotting factors, making the blood more prone to clotting. A patch or gel is absorbed through the skin and reaches the bloodstream directly, without that liver effect, so it does not raise the clotting proteins in the same way. The result is well evidenced: oral oestrogen carries a small added clot risk, and through the skin oestrogen does not.
Your own starting risk matters here too. A higher body weight, smoking, high blood pressure, migraine with aura, or an inherited clotting condition all raise the baseline risk of a clot, and they are part of why the route is chosen carefully rather than by default. For a woman with any of these, the transdermal route is usually the clear preference, and sometimes the deciding factor in whether to start at all.
None of this makes oral oestrogen dangerous. For a woman without those added risk factors, the extra clot risk from a tablet is still small, and if a patch or gel does not suit her, is not tolerated, or she simply prefers a tablet, oral oestrogen is a reasonable and safe option worth exploring.
Weighing your personal risk, together.
MHT is not a yes or no that can be read off a chart. Before starting, your doctor should take a proper history: your symptoms, your family history, your weight and blood pressure, whether you smoke, any history of clots, breast cancer, liver problems, migraine with aura, or unexplained bleeding. Some of these do not rule MHT out at all, but they may influence the type, the route, or the dose, and a few mean the decision needs specialist input. The point of that assessment is not to find reasons to say no. It is so that the choice you make together is based on your risks, not an average woman’s. Raise these things early, rather than ruling yourself in or out before the conversation.
The 2002 study, and why the fear outran the facts.
What the study actually found.
The Women’s Health Initiative was a large randomised controlled trial, the strongest kind of study for testing whether a treatment helps or harms. In 2002, the arm of the trial testing combined MHT was stopped early, because an interim look at the data suggested more breast cancer and more heart events than expected. That early stop, and the press conference around it, is what made the headlines. The trial itself was large and well conducted. The problem was not the study, it was how the result was reported, and who it was applied to.
The headline that frightened a generation.
The figure that travelled the world was a “26% increase in breast cancer”. That is a relative risk figure, and relative risk is the number that makes a small change sound enormous. In absolute terms, the kind that tells you how many women are actually affected, it amounted to fewer than one extra case per 1,000 women per year. A 26% increase on a small number is still a small number. Both figures are true at once, which is exactly why the way risk is reported matters so much. The same fact can frighten you or reassure you, depending only on which version you are handed.
The wrong population, and the window of opportunity.
The deeper problem was who was in the trial. The women averaged 63 years of age, and many were more than a decade past menopause, often already carrying cardiovascular risk. Starting oestrogen in arteries that may already carry early atherosclerosis behaves differently from starting it around the time of menopause, when the blood vessels are generally healthier. The trial also used oral conjugated oestrogen and an older synthetic progestogen, not the oestradiol through the skin and micronised progesterone more commonly used now. So it answered one specific question, what happens when you give that older formulation to women in their sixties, which is simply not the question a 52-year-old with hot flushes is asking.
Twenty years on, a more reassuring picture.
When the data were re-analysed by age, the harms looked very different. The oestrogen-only arm showed no increase in breast cancer, and in fact a reduction. The heart signal was driven by the older women who started late; the women who started near menopause did not show it. Later trials built specifically to test timing, KEEPS and ELITE, gave MHT to women close to menopause, and did not find the increase in heart problems that had shown up in the older WHI women. The picture we have now is far more reassuring. The cost of the fear from the WHI study was two decades of women left to suffer through symptoms a safe treatment could have eased.
The WHI study was not wrong. It was misread, over-generalised, and applied to women it never actually studied.
Weighing it up, for you.
Three things need to go on the scale.
A real decision about MHT is never made on the risks alone, or the benefits alone. Three things need to go on the scale together. The first is how much your symptoms are actually affecting your life, your sleep, your work, your relationships, because the benefit side of the sum is mostly about quality of life. The second is your personal baseline, your own risk factors and family history. The third is your age and how long it has been since menopause, because timing shapes both the benefit and the risk.
Every number here is an average. You are not.
Your own risk works on three levels, and a good consultation works through all three rather than reading you the population figure and leaving it there. The first is your baseline: your personal risk of a fracture, of breast cancer, of a clot, and of heart disease is set by your age, family history, weight, smoking, alcohol, and medical history, before any MHT is added. The second is the MHT itself, because the type and the route move those risks up or down, which is why the same decision can look quite different depending on what is prescribed and how. The third is your own weighing of it: how much your symptoms are costing you, against how much risk you are comfortable carrying.
For most symptomatic women, the balance favours treating.
For a woman under 60, or within 10 years of menopause, with symptoms that are bothering her and no strong reason to avoid it, the balance of benefit and risk favours treating. That is the mainstream position, from the Australasian Menopause Society and from NICE, and it is ours. The most favourable profile across the board is oestradiol through the skin with micronised progesterone: it takes the clot and stroke risk very nearly off the table, and it carries the more favourable breast cancer picture. It is worth saying clearly what MHT is, and is not, recommended for. It is first-line for symptoms and for protecting bone. It is not recommended as a treatment you take purely to prevent heart disease or dementia, however reassuring the emerging evidence is. Symptoms and bone are the reasons. The rest is good news that comes along with it.
Finally, no discussion about treatment is complete without noting the foundations. Nutrition, movement, sleep, alcohol, and stress are not optional extras in the menopausal years. They are the platform everything else sits on, and they have real, well-evidenced effects on symptoms and long-term health, and they are entirely risk free.
A shared decision, reviewed over time.
MHT is not a single yes or no, decided once and never revisited. It is started, reviewed, and adjusted as your symptoms and your risks change. The evidence shifts too. Menopause medicine is moving quickly, and the best advice when you start may be refined within a few years, which is one more reason these decisions should be consistently revisited over time. The decision is yours to make, and to keep making, with your doctor alongside you.
If you want to look it up, the studies behind this guide.
We have named studies throughout rather than hiding behind “research shows”, so here they are in one place, each linked to its source so you can read it yourself if you would like to. The kind of study matters: a randomised controlled trial can show cause, while an observational one can only suggest it. It is the difference between proof and a strong hint, and it is why the same “research shows” line can carry very different weight depending on what that research actually is.
| Study | What it is, and why it appears here |
|---|---|
| WHI (Women’s Health Initiative) | A large randomised controlled trial, and the 2002 study at the centre of this guide. Its early results drove the fear, and its later age-by-age re-analysis is part of what reassures us now. |
| DOPS (Danish Osteoporosis Prevention Study) | A randomised controlled trial designed around bone that also followed heart events and deaths for over 10 years. The main randomised evidence pointing towards fewer heart events and deaths in women who start early. |
| KEEPS and ELITE | Two randomised controlled trials built specifically to test the timing idea, the window of opportunity, by giving MHT to women close to menopause. |
| Nurses’ Health Study | A large American study that has followed tens of thousands of nurses since the 1970s, recording their health and their medication use, including MHT. Because it tracked women for decades, it is one of the main sources of long-term data on how women who use MHT fare over many years. |
| Million Women Study | A very large British study that followed over a million women and compared breast cancer rates between those who used MHT and those who did not. It found a higher rate among users and shaped a lot of the concern about MHT and breast cancer. Because of how it was designed, it tends to make that link look larger than the randomised trials do, which is a good example of why no single study should be read on its own. |
| E3N | A French study that followed around 100,000 women over many years. It matters most here because it compared different progestogens directly, and is one of the main reasons micronised progesterone is now thought to carry a more favourable breast cancer profile than the older synthetic types. |
| Danish and Finnish registry studies | Large observational studies built from national health records, and the source of much of the reassurance on mortality in women who start MHT around the time of menopause. |
The figures in this guide are drawn from international, mostly UK, datasets, because they are the best currently available and the Australian datasets are thinner. We use them as the most reliable estimates to hand, as of July 2026. The exact numbers may shift a little as more Australian data comes in, but the overall pattern, that the route, the type, and the timing are what shape the risk, holds across countries and is well supported.
If you are reading about the menopausal years more broadly, this guide has companions: our Menopause Deep Dive, our Perimenopause Deep Dive, and our Late Reproductive Stage Deep Dive, each of which links back here when the question of MHT comes up.
The full picture, in your hands.
You came here, most likely, because something left you frightened of a treatment that might help you. A headline, a relative’s story, a half-remembered news item from years ago. The picture is more reassuring, and more specific, than that fear. For most women starting around the time of menopause, the benefits of MHT are real and the risks are small.
This guide does not tell you what to decide, and it is not meant to. It is meant to put the same information your doctor is working from into your hands, so the two of you can decide together, looking at the same evidence. Now that you understand the why, you can weigh it for yourself. And you do not have to piece it together at 3am, deep in a ChatGPT spiral that should probably not have the last word on a decision that matters this much.